
Information
For US Healthcare Professionals
Patients can speak with a Nurse Educator who will reinforce how to use INBRIJA.
Patients can engage with leading PD experts and other people with PD on the management of the return of symptoms.
Videos and interactive information about the return of symptoms and treatment with INBRIJA.
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
Contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to hypertension risk. Discontinue use of nonselective MAO inhibitors at least 2 weeks prior to initiating INBRIJA.